5:56 AM
 | 
Mar 15, 2017
 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary

Patient sample and mouse studies suggest inhibiting LPAR1-ENPP2 signaling could help treat bronchiolitis obliterans syndrome following lung transplantation. In lung mesenchymal cells from lung transplant patients, ENPP2 levels were higher in patients with bronchiolitis obliterans...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >